443 related articles for article (PubMed ID: 17473845)
1. More than one reason to rethink the use of peptides in vaccine design.
Purcell AW; McCluskey J; Rossjohn J
Nat Rev Drug Discov; 2007 May; 6(5):404-14. PubMed ID: 17473845
[TBL] [Abstract][Full Text] [Related]
2. Epitope discovery and their use in peptide based vaccines.
Dudek NL; Perlmutter P; Aguilar MI; Croft NP; Purcell AW
Curr Pharm Des; 2010; 16(28):3149-57. PubMed ID: 20687873
[TBL] [Abstract][Full Text] [Related]
3. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.
Ulivieri C; Citro A; Ivaldi F; Mascolo D; Ghittoni R; Fanigliulo D; Manca F; Baldari CT; Li Pira G; Del Pozzo G
Immunol Lett; 2008 Aug; 119(1-2):62-70. PubMed ID: 18538862
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.
Purcell AW; Zeng W; Mifsud NA; Ely LK; Macdonald WA; Jackson DC
J Pept Sci; 2003 May; 9(5):255-81. PubMed ID: 12803494
[TBL] [Abstract][Full Text] [Related]
5. Totally synthetic peptide-based immunocontraceptive vaccines show activity in dogs of different breeds.
Walker J; Ghosh S; Pagnon J; Colantoni C; Newbold A; Zeng W; Jackson DC
Vaccine; 2007 Oct; 25(41):7111-9. PubMed ID: 17825958
[TBL] [Abstract][Full Text] [Related]
6. Design and development of synthetic peptide vaccines: past, present and future.
Bijker MS; Melief CJ; Offringa R; van der Burg SH
Expert Rev Vaccines; 2007 Aug; 6(4):591-603. PubMed ID: 17669012
[TBL] [Abstract][Full Text] [Related]
7. Peptidomimetics: modifying peptides in the pursuit of better vaccines.
Croft NP; Purcell AW
Expert Rev Vaccines; 2011 Feb; 10(2):211-26. PubMed ID: 21332270
[TBL] [Abstract][Full Text] [Related]
8. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
9. Viral peptide immunogens: current challenges and opportunities.
Azizi A; Diaz-Mitoma F
J Pept Sci; 2007 Dec; 13(12):776-86. PubMed ID: 17853502
[TBL] [Abstract][Full Text] [Related]
10. Synthetic peptides: prospects for vaccine development.
Milich DR
Semin Immunol; 1990 Sep; 2(5):307-15. PubMed ID: 2134015
[TBL] [Abstract][Full Text] [Related]
11. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
Patarroyo ME; Patarroyo MA
Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
[TBL] [Abstract][Full Text] [Related]
12. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of a multivalent, multiepitope vaccine construct.
Otvos L
Methods Mol Biol; 2008; 494():263-73. PubMed ID: 18726579
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem cell transplantation--validation of a peptide vaccine.
Schmitt A; Bechter C; Yao J; Goetz M; Maccari B; Schauwecker P; Wiesneth M; Schmitt M
J Immunol Methods; 2009 Apr; 343(2):140-7. PubMed ID: 19248785
[TBL] [Abstract][Full Text] [Related]
15. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
17. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry and peptide-based vaccine development.
Ovsyannikova IG; Johnson KL; Bergen HR; Poland GA
Clin Pharmacol Ther; 2007 Dec; 82(6):644-52. PubMed ID: 17971823
[TBL] [Abstract][Full Text] [Related]
19. Defined synthetic vaccines.
Zauner W; Lingnau K; Mattner F; von Gabain A; Buschle M
Biol Chem; 2001 Apr; 382(4):581-95. PubMed ID: 11405222
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
Melief CJ; van der Burg SH
Nat Rev Cancer; 2008 May; 8(5):351-60. PubMed ID: 18418403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
